Certara Products Archives

Case Study

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

In 2014, Eliglustat (Cerdelga®) was approved by the FDA as the first long-term treatment for…

Certara2021年8月26日

Case Study

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

Aripiprazole lauroxil (Aristada®) was approved by the FDA for treating schizophrenia in adults in October…

Certara2021年8月12日

Case Study

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…

Certara2021年8月12日

Blog

バリューコミュニケーションの成功：新薬の紹介

Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…

Certara2021年8月5日

Case Study

Simcyp Simulatorを使用するDDIレギュレトリーの広告塔：Ibrutinib (Imbruvica®)

Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…

Certara2021年7月29日

ビデオ

What is BaseCase?

Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…

Certara2021年7月20日

Case Study

鎌状赤血球症治療用のVoxelotor：用量予測モデルを活用して臨床試験を実施することなくDDIを予測

In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…

Certara2021年7月14日

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

Certara2021年6月18日

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Certara2021年6月11日

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Certara2021年6月11日

サターラの製品

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

バリューコミュニケーションの成功：新薬の紹介

Simcyp Simulatorを使用するDDIレギュレトリーの広告塔：Ibrutinib (Imbruvica®)

What is BaseCase?

鎌状赤血球症治療用のVoxelotor：用量予測モデルを活用して臨床試験を実施することなくDDIを予測

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

メルマガ登録

クイックアクセス

ソリューション

お問合せ